ReviewDer Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete2022
[Herpes zoster-prevention, diagnosis, and treatment].
Review in Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- The efficacy of serratus posterior superior intercostal plane block performed under ultrasound guidance in thoracic postherpetic neuralgia: a retrospective cohort study.BMC anesthesiology · 2026Article
- The impact of the 5A nursing model on pain in patients with postherpetic neuralgia: a randomized controlled trial.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Post-Herpetic Neuralgia: Review of Pathophysiology, Mechanisms, and Drug Treatment.Current neuropharmacology · 2026Review
- Comparative Mechanisms of DifferentMicroorganisms · 2025Article
- Brivudine as a successful treatment for herpes zoster combined with chickenpox.Postepy dermatologii i alergologii · 2025Article
- Disseminated Varicella-Zoster and Acute Liver Failure in a Patient With Crohn's Disease on Systemic Immunosuppression.ACG case reports journal · 2025Article
- Exploration of the Mechanism of Tongmai Xianxiang in Treating Postherpetic Neuralgia Based on Gas Chromatography-Mass Spectrometry Analysis and Network Pharmacology.International journal of genomics · 2025Article
- Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database.Scientific reports · 2024Article
- Varicella‑zoster virus‑associated meningitis followed peripheral facial palsy: A case report.Experimental and therapeutic medicine · 2024Article
- The Effect of CT-Guided Pulsed Radiofrequency Combined with Ozone Injection on Zoster-Associated Pain: A Retrospective Study.Journal of pain research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ) is a common skin disease resulting from a regionally limited reactivation of a latent infection with the varicella zoster virus (VZV). Despite its usually self-limiting course, HZ is associated with a considerable individual and public health burden of disease, particularly due to its high rate of postherpetic neuralgia (PHN).
objectivesTo improve knowledge of the current recommendations for the prevention, diagnosis and treatment. MATERIALS AND
methodsNarrative review and summary of current guideline recommendations.
resultsIn Germany, the recombinant VZV subunit zoster vaccine is recommended for all adults of 60+ years and for immunocompromised persons of 50+ years. The diagnosis of HZ is clinical; in case of uncertainty, laboratory investigations can help confirm the diagnosis. For patients with HZ ophthalmicus, HZ oticus or neurological complications, an interdisciplinary approach is advantageous. Antiviral treatment should be started as early as possible; various factors, including the duration and location of the disease, the patient's age and signs of a complicated course, serve to determine the indication to initiate an antiviral medication. The choice of the appropriate treatment depends, among other factors, on the intravenous availability, comorbidities and intake preferences. Early and sufficient analgesic treatment according to the WHO pain ladder and, if required, with anticonvulsant adjuvants is necessary to treat acute pain and to reduce the risk for PHN.
conclusionImplementation of the current recommendations for the prevention, diagnosis and treatment of HZ and PHN is important to reduce the high burden of disease and improve quality of life of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.